期刊
NATURE REVIEWS CLINICAL ONCOLOGY
卷 13, 期 10, 页码 597-610出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2016.76
关键词
-
类别
资金
- Department of Defense [PC130652, PC141474]
- National Institutes of Health [R01 CA 183857]
- A. Alfred Taubman Medical Research Institute
- Prostate Cancer Foundation
- Evans Foundation
- University of Michigan Prostate Cancer S.P.O.R.E. [P50 CA186786]
Over the past several years, analyses of data from high-throughput studies have elucidated many fundamental insights into prostate cancer biology. These insights include the identification of molecular alterations and subtypes that drive tumour progression, recurrent aberrations in signalling pathways, the existence of substantial intertumoural and intratumoural heterogeneity, Darwinian evolution in response to therapeutic pressures and the complicated multidirectional patterns of spread between primary tumours and metastatic sites. However, these concepts have not yet been fully translated into clinical tools to improve prognostication, prediction and personalization of treatment of patients with prostate cancer. The current and future clinical implications of 'omics' level knowledge is not only revolutionizing our understanding of prostate cancer biology, but is also shaping ongoing, and future clinical investigations and practice. In this Review, we summarize these advances, and the remaining challenges surrounding tumour heterogeneity and the ability to overcome treatment resistance are also described.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据